Sarepta Therapeutics Q4 2023 Adj EPS $0.82 Beats $0.01 Estimate, Sales $396.78M Beat $385.81M Estimate
Portfolio Pulse from Benzinga Newsdesk
Sarepta Therapeutics (SRPT) reported Q4 2023 adjusted EPS of $0.82, significantly beating the $0.01 estimate. Quarterly sales were $396.78M, surpassing the $385.81M estimate and marking a 53.54% increase from the previous year.
February 28, 2024 | 9:13 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Sarepta Therapeutics reported a significant beat on both EPS and sales for Q4 2023, with EPS at $0.82 against a $0.01 estimate and sales reaching $396.78M, exceeding estimates and showing a 53.54% YOY growth.
The substantial beat on both earnings per share and sales, coupled with a significant year-over-year growth, indicates strong financial health and operational efficiency. This performance is likely to positively influence investor sentiment and could lead to an increase in stock price in the short term.
CONFIDENCE 90
IMPORTANCE 95
RELEVANCE 100